All Topics Biosimilars Bone Metastases Brain Cancer Breast Cancer Business Management CAR T-cell Therapy Chronic Lymphocytic Leukemia Colorectal Cancer COVID-19 Gastrointestinal Cancer Genitourinary Cancers Gynecologic Oncology Head & Neck Cancers Hematologic Oncology Immuno-Oncology News Immunotherapy in GU Cancers Immunotherapy in Lung Cancer Immunotherapy in Melanoma Lung Cancer Mantle Cell Lymphoma Melanoma & Skin Cancer Multiple Myeloma Myeloproliferative Neoplasms Neoadjuvant HER2+ Non-Hodgkin Lymphoma Oncology Nursing News Ovarian Cancer Patient Resources Pediatric Hematology Oncology Precision Medicine in Oncology ® Prostate Cancer Sarcomas/TGCT Special Reports in Personalized Cancer Care Supportive Care
Browse by Series:
All Insights CDK4/6 Inhibitors for Hormone-Driven Breast Cancer Initial Therapy for Advanced Renal Cell Carcinoma Importance of Biomarker Testing for RET in Non Small Cell Lung Cancer Management of Neurofibromatosis Type 1 with Plexiform Neurofibromas (NF1 with PNs) Early Diagnosis of Myeloma: Guideline Compliant Testing The Emerging Role of Chemotherapy in Metastatic Prostate Cancer Update on Small-Cell Lung Cancer Relapsed or Refractory Metastatic CRC Evolution of Predictive Biomarkers for Metastatic CRC Phase III ALTA-1L Trial of Brigatinib for ALK-Rearranged NSCLC Emerging Therapies in HER 2-Positive Metastatic Breast Cancer Practical Management of Patients with Neuroendocrine Tumors New Indications for AR-Targeted Therapy on Prostate Cancer: Including ESMO 2019 Highlights Expanding Targets in NSCLC How Systemic Therapy is Combating Advanced CSCC The Future of RET Inhibitors in Non-Small Cell Lung and Thyroid Cancer Navigating the Complexities of HCC Inside the Clinic: Acute Graft-versus-Host Disease Key Considerations for Detecting and Targeting BRAF Mutations TRK Inhibitors: Evolution of a Tumor-Agnostic Treatment Approach Whats Next? Sequencing Later-Line Therapies in Metastatic CRC Advances in Treatment for ALK-Positive NSCLC Frontline Therapy In Follicular Lymphoma AFP as a Prognostic and Predictive Marker in HCC Inside the Clinic: Global Insights: Multidisciplinary Care of Stage III NSCLC Expanding Role of PARP Inhibitors in Advanced Ovarian Cancer Advances in BRAF-Targeted Therapy for Metastatic Melanoma ADT and the Risk of Major Adverse Cardiovascular Events Treatment Updates in Waldenstrom Macroglobulinemia Evolving Treatment Landscape of BTK Inhibitors in B-Cell Malignancies Emerging Approaches: Pancreatic Cancer Systemic Therapy Treating Mantle Cell Lymphoma: Role of BTK Inhibition Expert Perspective on the Treatment of Multiple Myeloma Novel “Tissue-Agnostic” Targeted Treatment Novel Therapeutic Agents for Acute Myeloid and Chronic Lymphocytic Leukemia How Systemic Therapy is Changing Advanced CSCC Best Practices for Utilizing Bone Targeted Therapy for Metastatic Prostate Cancer Community Focus: Expanding Use of CAR-T Therapy in Lymphoma Advances in the Treatment of Relapsed/Refractory Myeloma Novel Combination Approaches for Metastatic Kidney Cancer Academic Focus: CAR-T Therapy for Relapsed/Refractory NHL Clinical Update on Differentiated Thyroid Cancer Evolution of Predictive Biomarkers for Metastatic CRC Evolution of The Continuum of Care for Metastatic CRC Global Perspectives: FLT3 Inhibitors for AML Novel Predictive Biomarkers for Non-Small Cell Lung Cancer Combination Approaches for Metastatic Renal Cell Carcinoma Global Perspective: CDK4/6 Inhibitors in HR+ Breast Cancer Choosing an Endocrine Partner: Metastatic HR+ Breast Cancer Chemo-Immunotherapy for Non-Driver Metastatic Lung Cancer Practical Perspectives on Treatment of Advanced Gastric/GEJ Cancers TRK Inhibitors: A Tumor Agnostic Targeted Therapy Inside the Clinic: Interdisciplinary Care for Stage IV NSCLC New Treatment Strategies for Hepatocellular Carcinoma Antiangiogenic Therapy in the Current Landscape of NSCLC Treatment Updates in Chronic Lymphocytic Leukemia Treatment Strategies in Neuroendocrine Tumors Sequencing Strategies: Metastatic Pancreatic Adenocarcinoma Balancing Efficacy and Quality of Life in Refractory CRC New Concepts: Multimodal Approaches to Advanced NSCLC New Treatment Strategies for Follicular Lymphoma Treatment of Nonmetastatic Castration-Resistant Prostate Cancer Checkpoint Inhibitors in Advanced Bladder Cancer Managing Treatment Decisions for Ovarian Cancer Updates in Advanced Gastric/GEJ Cancer Treatment Case-Based Insights on Multiple Myeloma The Evolving Role of PARP Inhibitors in Ovarian Cancer Collaborative Care in Soft Tissue Sarcoma Addressing Unmet Needs in Liver Cancer Liquid Biopsy Use in Metastatic Non-Small Cell Lung Cancer Minimal Residual Disease Assessment in Lymphoid Malignancies The Evolving Landscape of Therapy for Follicular Lymphoma AR-V7 Testing in Prostate Cancer Optimal Therapeutic Management of Mantle Cell Lymphoma Checkpoint Inhibitors in Head and Neck Cancer Future Strategies in Kidney Cancer Treatment The Evolving Landscape of Immunotherapy for NSCLC Expert Perspective on Treatment of Polycythemia Vera Managing Chemotherapy Toxicity for 5-FU and Capecitabine Current Approaches in Advanced Non-Driver Lung Adenocarcinoma Next-Generation Agents for ALK-Positive NSCLC New Treatment Regimens for Previously Treated Myeloma Molecular Testing and EGFR-Mutant Non-Small Cell Lung Cancer Targeting Angiogenesis with Chemotherapy for Advanced Breast Cancer Treatment of ALK- or ROS1-Mutated Non-Small Cell Lung Cancer TKI-Resistant Chronic Myeloid Leukemia Acute Promyelocytic Leukemia (APL): Diagnosis and Treatment Chronic Myeloid Leukemia: Refining the Use of BCR-ABL TKIs Practical Guide on the Use of Immunotherapy in Melanoma The Era of Immunotherapy for Advanced Head & Neck Cancer Squamous Cell Carcinoma Precision Medicine in BRAF-Mutated Non–Small Cell Lung Cancer Novel Treatment Approaches in Glioblastoma EGFR-Targeted Therapy for NSCLC: Tolerability-Guided Dose Adjustment Improving Prostate Cancer Outcomes: A Model for Shared Care The Emerging Role of FLT3 Inhibitors in AML and ASM Global Insights on Anti-Angiogenic Therapy for Metastatic Lung Cancer Advanced Soft-Tissue Sarcoma: Integrating Monoclonal Antibody Therapy Treatment Approaches in Non-Driver Lung Adenocarcinoma Treating Beyond the First Line in HCC Extended Adjuvant Endocrine Therapy: The Role of Genomic Profiling Optimizing Treatment in Myeloproliferative Neoplasms Georgetown University's Approach to Treating Advanced Colorectal Cancer Relapsed Multiple Myeloma: Integrating Immunotherapy Pancreatic Cancer: Optimizing Patient Outcomes Implications of Tumor Sidedness in mCRC Novel PI3K Inhibitors in B-Cell Malignancies Global Expert Perspectives on Managing Excess Iron Expert Perspectives on Hereditary Testing in Breast Cancer Advancing Role of Immunotherapy in Multiple Myeloma Treatment of Advanced Head & Neck Squamous Cell Carcinoma Molecular Testing for Advanced Colorectal Cancer Multidisciplinary Care in Glioblastoma Treatment of Follicular Lymphoma Targeted Therapies in Advanced NSCLC Treating Adult Acute Lymphocytic Leukemia in 2016 Global Expert Perspectives: Metastatic Renal Cell Carcinoma 2015 Update: Metastatic Neuroendocrine Tumors 2015 Update on Chronic Lymphocytic Leukemia Global Expert Perspectives: Relapsed/Refractory Multiple Myeloma Advanced Gastrointestinal Stromal Tumors: Historical Perspective, Future Directions Modern-Day Treatment of Chemotherapy-Induced Nausea and Vomiting Guiding Patients With Colorectal Cancer Along Their Care Journey Advances in Targeted Therapy for Breast Cancer Treatment Pinpointing Primary Tumor Type and Mutations Improves Outcomes Integrating Novel Therapies into Treatment of B-Cell Malignancies Evolving Approaches for Controlling Liver Metastases in CRC Metastatic Prostate Cancer Update Perspectives on Treatment of Metastatic CRC Growing Options for RAI-Refractory Differentiated Thyroid Cancer Expert Review on the Multidisciplinary Management of Bladder Cancer Expert Perspectives on Advanced Pancreatic Ductal Adenocarcinoma Management of Immune Thrombocytopenia Recent Clinical Updates in the Management of Hodgkin Lymphoma Management of Chronic Iron Overload in Myelodysplastic Syndrome Identifying EGFR Mutations in NSCLC and Optimizing Therapy Treatment Strategies in NSCLC Clinical Management of Advanced Colorectal Cancer Treatment Evolution in Metastatic Breast Cancer Clinical Advances in HPV-Positive Head and Neck Cancer Treatment of Relapsed/Refractory Multiple Myeloma Rash Management Current Challenges in Oncology Nursing Brigatinib Regulatory Status in NSCLC VIDEO
Transcript: ALTA-1L met every one of its primary end points, so it’s clearly going to be approved in the first-line setting.
Ross Camidge, MD, PhD:
Lyudmila A. Bazhenova, MD: Our phase II ALTA trial, which was a second-line trial in patients who progressed on crizotinib, was updated at ASCO [the American Society of Clinical Oncology] 2018 annual meeting. In that trial, median progression-free survival on brigatinib was slightly over 16 months, which is also quite consistent with ALTA-1L trial. Remember, in the ALTA-1L trial, patients who were randomized to crizotinib were then allowed to cross over to brigatinib. In patients who crossed over to brigatinib, median progression-free survival was about 15 months. So we now have 2 different clinical trials using brigatinib in second line, which show very similar progression-free survival of about 15 to 16 months.
Transcript Edited for Clarity